Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma 1

Interventions

Cyclophosphamide 35Rituximab 33venetoclax 24ibrutinib 14Vincristine 14Prednisone 14Doxorubicin 14Gemcitabine 13pembrolizumab 12fludarabine 12Bendamustine Hydrochloride 11Etoposide 10obinutuzumab 9Filgrastim 9Dexamethasone 9Bortezomib 9fludarabine phosphate 8Mycophenolic Acid 8Drug Therapy 8ofatumumab 7Whole-Body Irradiation 7Sirolimus 7Peripheral Blood Stem Cell Transplantation 7Methotrexate 7Busulfan 7Therapeutics 6Radiotherapy 6Mesna 6Lenalidomide 6Ipilimumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Interleukin-18 × Lymphoid × Clear all
NCT00500058 2017-07-26

A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18

GlaxoSmithKline

Phase 1 Completed
24 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Neoplasms

NCT00085904 2008-10-13

Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas

GlaxoSmithKline

Phase 1 Completed
12 enrolled
Lymphoid

Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡